Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

SML2218

Sigma-Aldrich

SNS-032

≥98% (HPLC)

Synonym(e):

BMS-387032, N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C17H24N4O2S2
CAS-Nummer:
345627-80-7
Molekulargewicht:
380.53
MDL-Nummer:
MFCD09833875
UNSPSC-Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

powder

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL

Lagertemp.

−20°C

SMILES String

O=C(NC1=NC=C(SCC2=NC=C(C(C)(C)C)O2)S1)C3CCNCC3

InChI

1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)

InChIKey

OUSFTKFNBAZUKL-UHFFFAOYSA-N

Biochem./physiol. Wirkung

SNS-032 (BMS-387032) is a selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9 that regulate the cell cycle and transcription. It has IC50 values of 38 nM for Cdk2, 62 nM for Cdk7, and 4 nM for Cdk9. SNS-032 was in clinical trials for a variety of cancers including chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Rong Chen et al.
Blood, 113(19), 4637-4645 (2009-02-24)
Inhibitors of cyclin-dependent kinases (Cdks) have been reported to have activities in chronic lymphocytic leukemia cells by inhibiting Cdk7 and Cdk9, which control transcription. Here we studied the novel Cdk inhibitor SNS-032, which exhibits potent and selective inhibitory activity against
Calla M Olson et al.
Nature chemical biology, 14(2), 163-170 (2017-12-19)
Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of
Daniela Cihalova et al.
Cancer chemotherapy and pharmacology, 76(1), 105-116 (2015-05-20)
ATP-binding cassette (ABC) transporters play an important role in multidrug resistance (MDR) toward anticancer drugs. Here, we evaluated interactions of cyclin-dependent kinase inhibitors (CDKi) AT-7519, flavopiridol and SNS-032 with the following ABC transporters in vitro: P-glycoprotein (ABCB1), breast cancer resistance

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.